Organigram Invests Additional $2.5M in Hyasynth Biologicals

Organigram Holdings Acquires Motif Labs Ltd.

December 6, 2024

Consumer Products

Organigram Holdings Inc. acquired 100% of Motif Labs Ltd. for $90 million upfront consideration (C$50M cash and C$40M in Organigram common shares) plus up to C$10M contingent share consideration. The acquisition gives Organigram #1 market share in the Canadian recreational cannabis market, adds Motif's extraction and high‑volume vape/IPR manufacturing capabilities and a Southwestern Ontario distribution hub, and is expected to deliver >C$10M of cost synergies over ~24 months.

Organigram Holdings Inc. Acquires Laurentian Organic Inc.

December 21, 2021

Consumer Products

Organigram Holdings Inc. acquired all of the issued and outstanding shares of Laurentian Organic Inc. in a cash-and-share transaction with aggregate upfront consideration of CAD 36 million plus potential earnouts. The acquisition brings the Tremblant Cannabis and Laurentian craft brands into Organigram’s portfolio, strengthens its presence in Quebec, and expands its premium/hash product offering to accelerate revenue and EBITDA growth.

Organigram Acquires Collective Project Limited to Enter U.S. Hemp-Derived THC Beverage Market

April 1, 2025

Food & Beverage

Organigram Global Inc. acquired 100% of Collective Project Limited for approximately C$6.2 million upfront, with milestone and earnout payments linked to future beverage revenue that could bring total contingent consideration to C$24 million. The deal gives Organigram an immediate footprint in the U.S. hemp-derived THC beverage market and accelerates its entry into the cannabis beverage category in Canada by adding Collective Project’s ready-to-drink hemp/cannabis beverage portfolio and existing U.S. retail listings.

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.

Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B

December 6, 2021

Biotechnology

Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.

Symeres Acquires Organix Inc.

April 26, 2022

Biotechnology

Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.